Nicole Gregory – The Chief Commercial Officer – What we do for our Patients brought to you by The Community…
Browsing: Acute Lymphoblastic Leukemia
Michael Mitrani – Guiding Patients Through the Benefits Maze brought to you by The Community Oncology Alliance (COA) and The…
Timothy A. Masterson, MD Assistant ProfessorDepartment of UrologyIndiana University Medical Center and Vitaly Margulis MD Associate Professor of Urology of…
Nicholas G. Cost, M.D.Assistant Professor, Department of Surgery, Division of Urology University of Colorado School of Medicine discusses Hereditary Syndromes…
Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine presents Management of Kidney Cancer in Young…
E. Jason Abel MD, FACS of the University of Wisconsin presents Renal mass biopsy for risk stratification in RCC: benefits…
Mark Purdue, PhDOntario Institute for Cancer Research discusses Epidemiology and Genomics of Renal Cell Carcinoma at the Kidney Cancer Association…
Projecting Individual Probability for Developing Renal Cell Cancer presented by Xifeng Wu, MD, PHD, Professor and ChairDepartment of Epidemiology Betty…
At the iwNHL 2014, Dr Rafael Fonseca (Mayo Clinic, Arizona, USA) interviews Prof Keith Stewart (Mayo Clinic, Arizona, USA) and…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Wolfram Brugger (University of Freiburg, Villingen-Schwenningen,…
At the iwNHL 2014, Dr Steven Rosen (City of Hope National Medical Center, California, USA) describes the progress made in…
At the iwNHL 2014, Dr Mathias Rummel (Justus-Liebig University-Hospital, Gießen, Germany) describes his research investigating the use of bendamustine plus…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency,…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency,…
At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency,…
Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA),…
Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver,…
At the iwNHL 2014, Prof Michael Pfreundschuh (Saarland University Medical School, Homburg, Germany), Dr Rich Fisher (Fox Chase Cancer Center,…
At the iwNHL 2014, Prof Susan OBrien (MD Anderson Cancer Center, Texas, USA) and Prof Eva Kimby (Karolinska Institutet, Huddinge,…
At ESMO 2014, Dr Jennifer Temel is interviewed about the results of a phase III trial investigating the use of…
At ESMO 2014, Prof Tony Mok presents the results of the IMPRESS trial. This phase III trial showed that continuation…
At ESMO 2014, Prof Sandra Swain presents the results of the CLEOPATRA trial. This phase III trial in patients with…
During a press conference at ESMO 2014, Prof Frédéric Amant, University of Leuven, Leuven, Belgium, discusses his study on the…
At ESMO 2014, Prof Johan F. Vansteenkiste summarises the results of the MAGRIT trial, a phase III trial which showed…
During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of…
During a press conference at ESMO 2014, Dr Bernardo Leon Rapoport, The Medical Oncology Centre Rosebank, Johannesburg, South Africa, presents…
During the Saturday press conference at ESMO 2014, Professor David Currow describes results of Phase III data showing that a…
Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be…
The objective of this webinar was to provide an overview of the available front-line therapeutic options for patients with metastatic…
A study published online in the August 2014 edition of the Annals of Surgical Oncology shows that BluePrint (Agendia Inc)…
Tamoxifen (Soltamox/Nolvadex®; AstraZeneca), an antagonist of the estrogen receptor ? in ER?-positive breast cancer has been effective in most patients.…
The immune system has the ability to recognize tumors and to stop or control their development through a process known…
For more free video updates go to www.oncologyeducation.com Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not…
To view more free videos – visit www.oncologyeducation.com Profiling of protein expression, gene copy variations and mutations identified clinically relevant…
For additional free GI/Colorectal Cancer video updates, please go to www.oncologyeducation.com Chemo/CET and chemo/BV equivalent in OS in pts KRAS…
Dr Kenneth Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital,…
Dr Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Palumbo (University of Torina, Torina, Italy), Prof…
Prof Keith Stewart (Mayo Clinic, Scottsdale, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK),…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to the European Medical Journal from the 19th Congress…
Speaking to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour…
Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up
Prof. Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the phase III results from the RESONATE…
Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber…
Prof. Simon Rule from Plymouth Hospital, UK, discusses data presented at EHA19 on the second-generation oral BTK inhibitor, ONO-4059. One…
Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which…
Prof. Stephan Stilgenbauer from University of Ulm, Germany, defines ultra high-risk CLL (chronic lymphocytic leukemia) and comments on its implications…
Held annually in South Florida every January, The Symposium on Clinical Interventional Oncology (CIO) features a concentrated 2-day program renowned…